Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AHNSA
- Development stage
- Preclinical
- Lead developer
- Vanderbilt University
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AHNSA (Albumin-Hitchhiking Nanobody-STING Agonist) is an experimental immunotherapeutic platform designed to deliver STING (Stimulator of Interferon Genes) agonists systemically while minimizing systemic toxicity. The platform utilizes a nanobody that binds to endogenous albumin, allowing the therapeutic to hitchhike through the circulation and preferentially accumulate in tumor tissues. Once in the tumor microenvironment (TME), the STING agonist activates innate immune pathways, leading to the recruitment and activation of dendritic cells and M1 macrophages, and the subsequent enhancement of CD8+ T cell infiltration and function. AHNSA is primarily being investigated as a programmable adjuvant to improve the efficacy of adoptive cell therapies (ACT), such as CAR-T cells, in treating solid tumors by converting the immunosuppressive TME into a pro-inflammatory environment.
- Other names
- albumin-hitchhiking nanobody-STING agonist
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on AHNSA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AHNSA.